AI study using skin scar images to predict anti-PD-1 response
Part of Cancer, Skin clinical trials.
This study tests an artificial intelligence (AI) tool that looks at images of skin “peri-scar” areas to predict how well anti-PD-1 immunotherapy will work. It may help doctors better choose treatment for people with hard-to-operate (inoperable) melanoma or certain skin cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with inoperable stage III or IV melanoma, or inoperable squamous cell or basal cell skin cancer
- Your treatment plans match either the retrospective group (you already had anti-PD-1) or the prospective group (you are starting anti-PD-1 now)
- If in the retrospective group: you started anti-PD-1 for at least 90 days, with at least 6 months follow-up, and you are not on strong immune-suppressing medicines
- You must have clear photographs of the main tumor/scar area for the study, and the site must be imageable
- You must be able to sign a form allowing use of your images, and you must not be legally protected/under special legal protection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This study looks at how your immune system responds to PD-1/PD-L1 immunotherapy (drugs like Keytruda or Opdivo) for advanced melanoma, lung cancer, and similar cancers. It involves regular blood tests to track your immune cells, which may help doctors understand why these treatments work for some people better than others.
This study tests a very focused form of radiation for melanoma that has spread and has stopped responding to PD-1 (and sometimes CTLA-4) immunotherapy. It may help by shrinking progressing spots while keeping the immune treatment going.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.